Physicians' Academy for Cardiovascular Education

Lipids

Recently added learning

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Growing importance of lowering remnants, also in light of the obesity epidemic

3' education - June 3, 2019 - Børge Nordestgaard

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

Diverse study data confirm the rationale of intensive lipid-lowering

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

First time CV reduction is achieved with CETP inhibition

3' education - Aug. 29, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

3' education - Aug. 28, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

3' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)
##FULL_TITLE##

Lipid-lowering in the elderly - considering net benefit

3' education - Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

Statin lowers CV risk, in absence of LDL-c measurement

3' education - Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##FULL_TITLE##

CV benefit of daily statin therapy in the HOPE-3 trial

3' education - Apr. 18, 2016 - ACC 2016, Chicago, IL, USA - Jackie Bosch
##FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##FULL_TITLE##

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##FULL_TITLE##

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
##FULL_TITLE##

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##FULL_TITLE##

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##FULL_TITLE##

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##FULL_TITLE##

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##FULL_TITLE##

Lowering triglycerides while raising LDL-c: is this a problem?

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Børge Nordestgaard
##FULL_TITLE##

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##FULL_TITLE##

Collective amnesia on dietary fats and LDL-c

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Prof. Martijn Katan
##FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##FULL_TITLE##

John Chapman awarded for research on cholesterol particles

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Prof. John Chapman, Paris, France
##FULL_TITLE##

Harry Davis awarded with first Endo Award for discovery of ezetimibe

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Harry Davis
##FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##FULL_TITLE##

IMPROVE-IT: Congratulations, results & need for expert perspectives

3' education - Dec. 4, 2014 - AHA, Chicago - Dr Patrick O' Gara
##FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##FULL_TITLE##

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

PCSK9: The promise of a new target in lipid management

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014
##FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

10' education - Sep. 30, 2013
##FULL_TITLE##

Confirmation of lipid hypothesis in SEAS: Mortality risk stratification without lipids

3' education - July 28, 2011
##FULL_TITLE##

Lipids and CV risk

3' education - Oct. 3, 2009

On demand 10" video

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

PCSK9: The promise of a new target in lipid management

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014
##FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

10' education - Sep. 30, 2013

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD
Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%.

A study using data from the Copenhagen General Population Study showed that cholesterol in VLDL explains 50% of the MI risk from apoB-containing lipoproteins. Triglycerides in VLDL explain 0%. With poll.

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines.

The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.

Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD
 Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
In this video internist Kees Hovingh discusses why screening for FH is important and tools used for its diagnosis.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD
There has been confusion about the relationship between HDL-c and CV risk in the past and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD
At the end of the FOURIER trial studying evolocumab, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

The mechanism of action of bempedoic acid

Feb. 2, 2020

Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD
A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD
Prof. Laufs points out the new emphasis in the ESC/EAS Dyslipidaemia Guidelines on high-risk patients, and shares evidence that forms the rationale for the treatment recommendations.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD
Robert Giugliano explains that very low LDL-c is safe, using data of recent clinical trials with LDL-c lowering drugs.

Robert Giugliano explains that very low LDL-c levels are safe, using data of recent clinical trials with LDL-c lowering drugs.

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia
The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.

Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD
Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.

Before listing the differences between the AHA/ACC 2018 and ESC/EAS 2019 dyslipidemia guidelines, prof. Ballantyne shares common themes and shared concept across the guidelines.

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD
In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.

In the FOURIER trial, evolocumab reduced LDL-c by ~60% in patients with established CVD. Prof. Sabatine highlights subgroups of high-risk patients who benefit most from treatment with this PCSK9 inhibitor.

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD
Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.

Prof. Kastelein discusses new strategies to target PCSK9, including twice-a-year injections of inclisiran and a newly developed oral PCSK9 inhibitor.

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach
Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

ESC 2019 Prof. François Mach presents results of the EVOPACS trial, showing decreased LDL-c levels with evolocumab vs. placebo at 8 weeks after ACS in patients with STEMI and NSTEMI.

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein
Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.

ESC 2019 Prof. John Kastelein shares the results of the phase 3 ORION-11 trial with inclisiran in ASCVD and risk equivalent patients not at LDL-C goal.

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano
Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

ESC 2019 Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach
Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina
Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

Lp(a) meeting Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD
Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Lp(a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME
Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.

Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD
Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Lp(a) meeting Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas
Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD
Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD
Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

Growing importance of lowering remnants, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 3, 2019 - Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Cholesterol guidelines in need of major changes?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

Are very low LDL-c levels safe?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

LDL-c as target in cardiology: The road towards lower targets

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Guidelines and the role of non-statin therapies for high risk ASCVD patients

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME
There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

Lowering Lp(a) potently and safely with antisense technology

AHA 2018 - Chicago, IL, USA

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD
Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

AHA 2018 Lp(a) is a highly prevalent risk factor, with to date no therapy to lower its levels. A phase 2b study now shows that an antisense oligonucleotide potently lowers production of Lp(a), to optimal levels.

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

AHA 2018 - Chicago, IL, USA

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA
Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France
In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa
Whilst lipidology relies mostly on routine laboratory investigations, special investigations are often required to describe specific lipids, lipoproteins and genetic problems. Prof. Marais gives an overview of those investigations.

Whilst lipidology relies mostly on routine laboratory investigations, special investigations are often required to describe specific lipids, lipoproteins and genetic problems. Prof. Marais gives an overview of those investigations.

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in  persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

Estimating CV risk and treatment benefit

Clinical updates in management of cardiovascular risk (4/4)

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands
Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.

Charlotte Koopal discusses the pathofysiology of familial dysbetalipoproteinemia, how to diagnose the disease and recommendations for treatment.

The role of lipids in CVD prevention: Lessons learned about statins

Clinical updates in management of cardiovascular risk (2/4)

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME
For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa
Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Prof. Frederick Raal describes the prevalence and phenotypic variability of FH. Novel therapies have changed FH from a lethal disorder to a manageable dyslipidaemia.

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA
Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c.. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA
In a debate about muscle symptoms in patients on statins, Thompson defended the statement that these symptoms are real by discussing the results of several clinical trials and studies examining the biochemical mechanism.

VBWG at ACC 2018 In a debate about muscle symptoms in patients on statins, Thompson defended the statement that these symptoms are real by discussing the results of several clinical trials and studies examining the biochemical mechanism.

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.

Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA
Prof. Libby discusses IL-1β as a target for atherosclerosis therapy, a strategy that was evaluated in the CANTOS trial, which tested the monoclonal antibody canakinumab.

Prof. Libby discusses IL-1β as a target for atherosclerosis therapy, a strategy that was evaluated in the CANTOS trial, which tested the monoclonal antibody canakinumab.

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France
Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab

Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME
Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.

Prof. Stroes describes the 3 pathways involved in progression of atherosclerosis and new algorithms to reduce residual risk with personalized therapy.

The patient with inflammatory residual risk: Who is it?

Also as CME e-learning

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME
Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.

Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA
Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.

Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction

Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA
Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.

Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Inflammation Expert Opinions Il prof. Raffaele De Caterina spiega perché CANTOS è uno studio clinico importante. E’ il primo studio clinico che dimostra che un farmaco anti-infiammatorio influenza favorevolmente importanti eventi cardiovascolari, e pertanto può diventare una terapia da inserire nell’armamentario terapeutico in aggiunto agli attuali trattamenti.

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Inflammation Expert Opinions Prof. Raffaele de Caterina explains why CANTOS is an important trial. It is the first trial showing that an anti-inflammatory drug can affect important CV outcomes and thus may be a convenient therapy in addition to current treatment strategies.

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Inflammation expert opinions

5' education - Aug. 27, 2017
According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Inflammation Expert Opinions According to prof. Ulf Landmesser, the CANTOS trial shows that inflammation is crucial for disease progression and that targeting inflammation as a risk factor may have important implications for high-risk populations.

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Inflammation expert opinions

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Inflammation Expert Opinions Prof. Ulf Landmesser: Die CANTOS Studie zeigt erstmalig, dass eine Interleukin-1 Beta Inhibition, d.h. eine spezifische Entzündungshemmung, das kardiovaskuläre Risiko nach akutem Koronarsyndrom reduzieren kann.

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

Inflammation expert opinions

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process.

Inflammation Expert Opinions Prof. Wolfgang Koenig states that the CANTOS trial shows that inflammation plays a causal role in the atherogenic process. Blocking this inflammation may be an additional treatment option beyond lipid lowering for CV risk reduction.

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon
Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica.

Inflammation Expert Opinions Lina Badimon explica por qué el bloqueo de la inflamación puede representar un beneficio clínico significativo, debido al importante papel de la inflamación en la formación de la placa aterosclerótica. Los resultados de CANTOS pueden representar el inicio de una nueva era en la prevención cardiovascular.

Diverse study data confirm the rationale of intensive lipid-lowering

ESC 2017 - Barcelona

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.

Imaging components of plaque not more informative than burden of plaque

ESC 2017 Barcelona

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when PCSK9 inhibitor evolocumab was added to intensive statin-treatment.

ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

First time CV reduction is achieved with CETP inhibition

ESC 2017 - Barcelona

3' education - Aug. 29, 2017
In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.

ESC 2017 In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

ESC 2017 A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

Natural randomisation shows that mode of LDL-lowering determines CV benefit

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
CETP inhibition is an exception to the rule that LDL reduction leads to CV event reduction. The Mendelian randomization approach was employed to investigate this exception.

ESC 2017 CETP inhibition is an exception to the rule that LDL reduction leads to CV event reduction. The Mendelian randomization approach was employed to investigate this exception.

LDL-c still reduced after 1 year with siRNA against PCSK9

ESC 2017 - Barcelona

3' education - Aug. 28, 2017
Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

ESC 2017 Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

Invitation by Prof Peter Sever to attend the Clinical Dialogue on Lipids & Diabetes to be held on December 6 & 7 in Stratford Upon Avon, United Kingdom

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works, it is safe, and you cannot force biology

PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA
Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

PCSK9 Expert Opinions Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
Prof. Richard Hobbs states that PCSK9 inhibition reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
Dr. Paul M. Ridker states that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

PCSK9 Expert Opinions Dr. Paul M. Ridker states that from FOURIER and SPIRE it becomes clear that further lowering of LDL-c during a longer period of time safely translates into lower rates of CVD.

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Kausik Ray describes the absence of a  J-shaped curve in the PCSK9 outcome trials,  meaning there is no apparent diminution of benefit to very low LDL.

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy and puts the data into perspective of other trials and molecules.

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017
Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patient, as a consequence of development of antibodies against the drug.

ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
Implementation of PCSK9 inhibition in clinical practice before the outcome data

CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

AHA 2016 Prof. John JP Kastelein, MD summarises the promising results of the pivotal GLAGOV and ORION-1 trials, presented at the AHA 2016. In GLAGOV, atheroma regression was seen with evolocumab treatment, and in ORION-1 RNA-interference directed against PCSK9 yielded durable LDL-c lowering effect.

Lipid-lowering in the elderly - considering net benefit

3' education - Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##KEY_PHRASE##

AHA 2016 As a chair of the 2013 ACC/AHA cholesterol guidelines, Neil Stone sheds light on the considerations behind the recommendations on lipid-lowering in the elderly, both for primary and secondary prevention.

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##KEY_PHRASE##

AHA 2016 The ORION-1 study evaluated different doses of inclisiran, which prevents hepatic PCSK9 production by RNA interference. With a single injection, about 50% LDL-c reduction was achieved, and maintained through 90 days.

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##KEY_PHRASE##

AHA 2016 Prof. Wouter Jukema summarises new insights presented at the AHA, including failing HDL-modifying therapy in the MILANO-PILOT study, a promising effect of a PCSK9 antibody on top of statin on atheroma volume in GLAGOV, and profound LDL-lowering after blocking PCSK9 synthesis in ORION-1.

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##KEY_PHRASE##

AHA 2016 Dr. Steve Nissen shares the results of the GLAGOV study, in which evolocumab added to a statin yielded more regression of atheroma volume than statin therapy alone, with an even stronger response in patients with relatively low LDL-c levels.

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016
A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

John Kastelein, MD (Amsterdam, The Netherlands) indicates the position of PCSK9-inhibitors in current lipid management, especially in patients with FH.

Statin lowers CV risk, in absence of LDL-c measurement

Jackie Bosch (Hamilton, ONT, Canada)

3' education - Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##KEY_PHRASE##

Participants in the HOPE-3 study were recruited based on their CV risk, without requesting a baseline LDL-c measurement. In the intermediate risk population, randomisation to rosuvastatin yielded a 25% CV risk reduction. 

CV benefit of daily statin therapy in the HOPE-3 trial

3' education - Apr. 18, 2016 - ACC 2016, Chicago, IL, USA - Jackie Bosch
##KEY_PHRASE##

ACC 2016 Jackie Bosch (Hamilton, ONT, Canada) shares the results of the cholesterol-lowering arm of the HOPE-3 study, in which rosuvastatin 10 mg daily yielded a 27% reduction in LDL-c and reduced CV events. The CV benefit was consistent across various subgroups.

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##KEY_PHRASE##

ACC 2016 Data from the GAUSS-3 study show that muscle-related statin intolerance is a real problem and PCSK9 inhibition with evolocumab dramatically reduces LDL-c in these patients.

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##KEY_PHRASE##

ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##KEY_PHRASE##

ACC 2016 Stephen Nicholls discusses the results of the ACCELERATE-study, in which the favourable effects of the CETP-inhibitor evacetrapib on cholesterol did not translate into any reduction in the primary endpoint.

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##KEY_PHRASE##

The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##KEY_PHRASE##

Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Kallend shares data of a phase I trial with ApoA1-Milano-POPC (MDCO216), which was well-tolerated and showed an increase in efflux in patients with recent CAD but who are clinically stable.

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##KEY_PHRASE##

Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Kontush shared data of a study into the lipidome of HDL particles. HDL particles with phosphatidylserine showed more cardioprotective properties, including antiinflammatory activity, than those without phospatidylserine, both in vitro and in mice.

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Bertrand Cariou presents data of a study that investigated the willingness of patients and physicians to use self-injections (either by prefilled pen or a prefilled syringe) to administer the PCSK9-antibody alirocumab.

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##KEY_PHRASE##

Lipid MC 2015 Prof Evan Stein explains why it is important that more international physicians become actively involved in FH research, and he invites those interested to become an FH investigator, which will benefit both patients and the investigator.

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##KEY_PHRASE##

Lipid MC 2015 Prof. Kausik Ray highlights differences in recommendations between international lipid guidelines, which originate in differences between the scopes of the documents. These differences have consequences for the recommended approach to reduce CV risk in patients.

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Harold Bays shares the results of treatment with a new potent chemical entity, cosabutate, hich safely modifies triglyceride and lipid fraction levels in patients with hypertriglyceridaemia.

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs The ODYSSEY CHOICE I evaluated the efficacy of PCSK9-inhibitor alirocumab given once every four weeks instead of every two weeks. Prof. Eli Roth considers this dosing scheme a good option for patients who prefer monthly injections.

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##KEY_PHRASE##

Lipid MC 2015 Prof. Kausik Ray provides several reasons why non-HDL-c may be a better lipid parameter than LDL-c to assess risk, to identify high-risk patients and guide treatment.

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##KEY_PHRASE##

Lipid MC 2015 Dr. Kees Hovingh discusses recent insights into the actual prevalence of homozygous and heterozygous FH, how FH patients can best be identified, and how they should be managed.

Lowering triglycerides while raising LDL-c: is this a problem?

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Børge Nordestgaard
##KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Prof. Børge Nordestgaard (Copenhagen, Danmark) discusses results with a novel specific PPAR alpha-modulator that lowers triglycerides, remnant cholesterol and apoCIII, but raises LDL-c. A Danish registry suggests that this combination may actually be a beneficial lipid profile.

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##KEY_PHRASE##

ISA 2015 Allyson Morton (Boston, USA) presented a follow-up study of the EVOLVE trial, which showed that omega-3 carboxylic acid treatment reduced apoCIII levels in whole plasma, and in HDL and LDL. LDL levels without apoCIII were reduced, which has a weak relation to CV risk.

Collective amnesia on dietary fats and LDL-c

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Prof. Martijn Katan
##KEY_PHRASE##

ISA 2015 Prof. Martijn Katan (Amsterdam, The Netherlands) responds to the report of the US 2015 Dietary Guidelines Advisory Committee stating that cholesterol intake does not raise serum LDL-c. Older evidence from randomised trials arguing this statement seems to be forgotten.

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##KEY_PHRASE##

ISA 2015 In a Clinical Breakthrough Session, dr. Paul Barton Duell (endocrinologist, Portland, USA) presented a striking reduction of MACE with treatment with the antisense oligonucleotide against apoB mRNA mipomersen in a very high risk population.

John Chapman awarded for research on cholesterol particles

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Prof. John Chapman, Paris, France
##KEY_PHRASE##

ISA 2015 During the opening session of ISA2015 in Amsterdam, prof. John Chapman (Paris, France) was awarded with the Antonio M. Gotto, Jr. Prize. He describes how his work on lipid transport, via studying the complexity of lipoprotein particles, has led to the identification of new pharmacological targets.

Harry Davis awarded with first Endo Award for discovery of ezetimibe

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Harry Davis
##KEY_PHRASE##

ISA 2015 During the opening session of ISA2015 in Amsterdam, dr. Harry Davis (Gaithersburg, Maryland, USA) was awarded with the first Endo Award - named after Akira Endo whose work led to the invention of statins. Davis is the father of the LDL-lowering and CV event reducing drug ezetimibe. 

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##KEY_PHRASE##

Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction.

IMPROVE-IT: Congratulations, results & need for expert perspectives

3' education - Dec. 4, 2014 - AHA, Chicago - Dr Patrick O' Gara
##KEY_PHRASE##

Dr. Patrick O' Gara, Boston, and ACC President comments on the results of IMPROVE-IT trial as presented at the AHA meeting in Chicago

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##KEY_PHRASE##

Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##KEY_PHRASE##

Dr. Michael J Koren MD, Jacksonville, FL, USA, shares his rationale for targeting PCSK9, based on epidemiology and recent clinical developments and discusses implications for future lipid management 

First European experience with human MTP-inhibitor in HoFH

Dr. Jeanine Roeters van Lennep

10' education - Oct. 24, 2014
##KEY_PHRASE##

Jeanine Roeters van Lennep, MD PhD (Erasmus MC, Rotterdam, The Netherlands) discusses management of homozygous familial hypercholesterolaemia (HoFH).

Biology and validation of PCSK9 as a novel target to lower LDL-C

Prof. John JP Kastelein

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##KEY_PHRASE##

Lecture by Prof. John Kastelein, Amsterdam, The Netherlands, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research' held during ESC2014 in Barcelona

PCSK9: The promise of a new target in lipid management

Prof. John E Deanfield, UCL, London

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##KEY_PHRASE##

Prof. John E Deanfield, London introducing the rationale for PCSK9 inhibition with a lecture held during an EBAC accredited symposium on innovations in lipid management at ESC 2014 in Barcelona

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##KEY_PHRASE##

A mechanism of action animation on the potential role of the inhibition of PCSK9 with a monoclonal antibody

Emerging therapies to lower LDL-cholesterol

Prof. Erik Stroes, MD

10' education - May 8, 2014
##KEY_PHRASE##

Prof. Erik Stroes describes new treatments to lower LDL-cholesterol: PCSK9-inhibitors, ApoB antisense and MTP-inhibitors, discussing several studies presented recently at the ACC-congress.

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

Evan Stein, ESC, August 31, 2013

10' education - Sep. 30, 2013
##KEY_PHRASE##

The symposium PCSK9: the new lipid target in preventive cardiology?  ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013. A videopresentation from the lecture by Evan Stein Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling? is now available on this website.

Confirmation of lipid hypothesis in SEAS: Mortality risk stratification without lipids

3' education - July 28, 2011
##KEY_PHRASE##

Prof. Ingar Holme, Norway, discusses the background and the main results of the SEAS trial.

Lipids and CV risk

3' education - Oct. 3, 2009
##KEY_PHRASE##

**Which lipids matter? **Dr. Philip Barter The Heart Research Institute, Sydney Australia